Impel NeuroPharma (NASDAQ:IMPL) is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier (BBB) using direct nose-to-brain delivery. Direct brain delivery may allow for lower dose volumes, decreased systemic exposure and faster onset than traditional delivery routes. The firm's Pressurized Olfactory Delivery (POD) device uses dynamic airflow to deliver therapeutics to the brain via the upper nasal cavity and olfactory epithelium. This region represents a unique pathway to bypass the blood-brain barrier and allow neuro-active compounds and biotechnology products to be readily absorbed into the brain. The device incorporates a safety interlock, is cost-effective to manufacture, comfortable to use, the size of an asthma-inhaler, disposable, composed of medical grade plastics and uses FDA-approved excipients. IThe most recent application organizes around migraines and Parknmson Disease. mpel's pipeline includes analgesics, chemotherapeutics and anti-retrovirals.